ACPU
ARIA

Arrowgrass Capital Partners (US)’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-200,000
Closed -$3.68M – 224
2013
Q3 		$3.68M Buy
+200,000
New +$3.88M 0.14% 120

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ARIA Position: Q1 2015 in Review

Arrowgrass Capital Partners (US) sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2015, closing a stake of 100,000 shares — an estimated $687K sold.

Arrowgrass Capital Partners (US) first reported a position in ARIA in Q3 2013 and held it in 3 quarters. The position peaked at $1.4M in Q3 2013. 193 funds tracked by Wall St. Rank hold ARIA as of Q1 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 100,000 Ariad Pharmaceuticals Inc shares in Q1 2015, an estimated $687K.
  • Arrowgrass Capital Partners (US) first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 3 quarters.
  • Arrowgrass Capital Partners (US)'s Ariad Pharmaceuticals Inc position peaked at $1.4M in Q3 2013.
  • 193 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2015, filed 15 May 2015.